Homology Medicines, a preclinical biotech developing a gene therapy delivery platform for rare diseases, announced terms for its IPO on Monday.
The Bedford, MA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Homology Medicines would command a fully diluted market value of $529 million.
Homology Medicines was founded in 2015 and plans to list on the Nasdaq under the symbol FIXX. BofA Merrill Lynch, Cowen & Company and Evercore ISI are the joint bookrunners on the deal. It is expected to price during the week of March 26, 2018.
